Items Tagged ‘Melanoma’

March 4, 2019

FDA Approves Keytruda for Adjuvant Treatment of Melanoma

By

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC […]

View full entry

Tags: Melanoma, News


February 25, 2019

Isatuximab – Promising for Treatment of Myeloma

By

A phase 3 comparative clinical trial evaluating Isatuximab has met the primary endpoint of delaying cancer progression in patients with relapsed/refractory multiple myeloma. Multiple myeloma is the second most common hematologic malignancy, with more than 138,000 new cases worldwide each year. Multiple myeloma remains incurable in the vast majority of patients, resulting in significant disease […]

View full entry

Tags: Melanoma, News


February 21, 2019

Keytruda Approved for Treatment of Stage III Melanoma

By

The U.S. Food and Drug Administration (FDA) has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete surgical resection. Adjuvant Therapy in Melanoma Melanoma is separated into five staging categories (stages 0-4).  Stage 3 melanoma is a cancer that has spread to the regional lymph nodes but […]

View full entry

Tags: Melanoma, News


January 25, 2019

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma

By

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile. CHICAGO (January 25, 2019): Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not […]

View full entry

Tags: Melanoma, News


May 7, 2018

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma

By

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.1 About Melanoma  Stage III melanoma includes cancers of any thickness that have spread to the […]

View full entry

Tags: adjuvant treatment, BRAF V600E, dabrafenib, mekinist, Melanoma, News, precision cancer medicines, stage III, tafinlar, trametinib, V600K mutations


April 5, 2018

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma

By

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1 About Melanoma  Metastatic melanoma refers to skin cancer that has spread from […]

View full entry

Tags: BRAF 600, Mekinist rametinib, Melanoma, Metastatic melanoma treatment, News, Precision Cancer Medicine, Skin Cancer, Tafinlar (dabrafenib)


January 15, 2018

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma

By

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected high-risk melanoma, met the primary endpoint of improving recurrence-free survival. Adjuvant Therapy in Melanoma Melanoma is separated into five staging categories (stages 0-4).  Stage III […]

View full entry

Tags: Melanoma, News


January 12, 2018

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma

By

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug keytruda (pembrolizumab) with a herpes virus called T-VEC (talimogene laherpareovec). Researchers found that the […]

View full entry

Tags: immunotherapy, keytruda, Melanoma, News, Precision Cancer Medicine, T-VEC, targeted therapy


January 9, 2018

FDA Approves Opdivo for Adjuvant Treatment of Melanoma

By

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Opdivo was previously approved for the treatment of patients with unresectable or […]

View full entry

Tags: malignant melanoma, Melanoma, News, nibolumab, opdivo, Precision Cancer Medicine, Yervoy


January 8, 2018

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

By

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical trial.  Based on data from this trial, ulixertinib has received the U.S. Food and Drug Administration’s Fast Track […]

View full entry

Tags: Colon Cancer, ERK inhibitor, Lung Cancer, MAPK/ERK, Melanoma, News, Precision Cancer Medicine, targeted therapy, ulixertinib


September 28, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy


July 2, 2013

Investigational Melanoma Drug Shrinks Tumors in Phase III Trial

By

In a Phase III clinical trial, the investigational drug T-VEC (talimogene laherparepvec) produced durable responses in people with advanced melanoma.  These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Of the more than one million new diagnoses of skin cancer each year, roughly 76,000 involve melanoma. More […]

View full entry

Tags: Melanoma, Stage III Melanoma, Stage IV Melanoma


July 1, 2013

Anti-PD-1 Drugs Promising for Advanced Melanoma

By

In Phase I clinical trials, investigational drugs that target a protein known as PD-1 are showing promise for the treatment of advanced melanoma. Results from two of the trials were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology and also published in the New England Journal of Medicine. Of the more […]

View full entry

Tags: Melanoma, Stage III Melanoma, Stage IV Melanoma


June 26, 2013

Selumetinib Active Against Melanoma of the Eye

By

In a Phase II clinical trial, the investigational targeted drug selumetinib resulted in tumor shrinkage in half of patients with advanced melanoma of the eye. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology. Melanoma of the eye—also known as uveal melanoma—is a rare cancer that affects approximately […]

View full entry

Tags: Melanoma, Stage IV Melanoma


May 6, 2011

Many Young Women Continue to Tan

By

According to a survey by the American Academy of Dermatology, use of tanning beds remains a common practice among young, white women. Intentional outdoor tanning was also widely reported. Sun exposure has long been linked with skin cancer, and a growing body of evidence indicates that tanning beds also increase risk. Exposure to sunlamps or […]

View full entry

Tags: General Skin Cancer, Health and Wellness, Melanoma, Screening/Prevention Melanoma, Skin Cancer